Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules - Wikidata - wikimedia - TriplyDB

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

http://www.wikidata.org/entity/Q30496972

about

High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.A molecular and structural mechanism for G protein-mediated microtubule destabilization.Antibody-DM1 conjugates as cancer therapeutics.A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents Noscapine recirculates enterohepatically and induces self-clearance.Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Optimising the delivery of tubulin targeting agents through antibody conjugation.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Experimental approaches in the treatment of multiple myeloma.Industrial natural product chemistry for drug discovery and development.Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.Modeling the effects of drug binding on the dynamic instability of microtubules Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.In vivo biotransformations of antibody-drug conjugates.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Emerging antibody-drug conjugates for treating lymphoid malignancies.Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site Protein based therapeutic delivery agents: Contemporary developments and challenges.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Promising therapies in multiple myeloma.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

P2860

Q28543403-4DB0DC19-847E-46E3-B121-3609D5182DA7 Q30498188-A416F03D-4C61-45EC-B91E-433AA8648582 Q34177359-AA143354-DC6B-4503-A4D9-A61892D14EB5 Q34281123-E9071BB6-9E10-4A91-BD85-3329122D5019 Q34313834-C7FA50C8-935F-4B1E-9C52-14C76A598B67 Q34998509-1C2CF32E-1F57-4389-937D-7E22AF9AA21A Q35006348-D9CB5839-897B-4FDB-99F9-BD918A2008BA Q35459059-EEE12DCC-E6B9-4CF2-A194-C52C91FEFAA9 Q35737288-F7EA2625-3EE5-4DD5-A71E-91FD42D04199 Q35893886-8B22CD19-AC5F-4216-93AF-E83D41DEDDCF Q36061613-0C84C7FA-018F-4475-A1FE-296EF8B565FB Q36256669-4BB5F4E7-ED94-4150-9539-D11915DDC144 Q36745332-7BBB66EA-1E5C-4129-8653-40D414EEBD0D Q36824455-D019D40C-C29D-4AC4-B58C-4C7D7C2B84ED Q36958365-F5DCFE82-B6E2-4F1B-8A60-BE1A5EB37A68 Q37126006-23507146-23B3-47AA-B6E5-DF478E7D74DB Q37447340-B080EA54-095F-4B3B-90C6-F1D7770112F9 Q37585671-5D61CBA4-929F-4B6D-ABB4-A1449CA0CCEF Q37600390-93646DA7-E2F7-4F26-A38A-00615478B2F6 Q38024991-C4587C29-E49C-4379-9F3C-32C474259CB5 Q38073792-D4E9A086-56A4-49CE-941F-4B132F91888D Q38095958-A8F9B850-5F7A-4E16-8F16-B0C1F4FA59F5 Q38154186-41ACB59F-6641-493E-91FC-800801744EBB Q38166831-704966A7-5DB2-4974-B17C-0AF78031B39B Q38341603-E2B74B28-E3CA-4C41-9987-8923B5E9F800 Q38537257-C9249F4C-DBA5-4460-BB88-537C95544E79 Q38557525-0E7D929E-0CC7-4A0B-ABF5-D7499EC2A3EC Q38624597-7916AAB6-F25B-469D-8C5F-F8CF46DEDD00 Q38632313-F7F56426-4CF3-41C4-8E30-E95CA7EC1EB4 Q38755443-5E79EC7E-6494-451A-800E-6C21A11ACDC7 Q38922319-4EAED6A0-3369-460C-BDC6-BAF99C28D2D1 Q39030222-880C164E-0D0E-4877-982F-A9EF607F74B6 Q39079147-C773A39C-36D4-437A-923D-DC36A2D96A6A Q39273739-576C02E5-BFC4-46DB-BA93-2A8C0C647703 Q39645683-15F5A4F9-92C1-4CCF-A5DF-2051C805A85C Q42581682-FFB96B6E-2B65-4FE4-B94F-86906991461E Q43525091-07605CA5-7778-448C-976F-42A3802A98EB Q44957894-DFCBA271-E4A0-4C81-A286-0981F4BF7422 Q47136161-D8F895EB-CED5-407F-8661-8BD51946BBA2 Q47661007-2E4C155C-BF4A-462F-9CFF-444A39EFE313

P2860

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

http://www.wikidata.org/entity/Q30496972

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Maytansine and cellular metabo ...... ics by binding to microtubules

@ast

Maytansine and cellular metabo ...... ics by binding to microtubules

@en

type

label

Maytansine and cellular metabo ...... ics by binding to microtubules

@ast

Maytansine and cellular metabo ...... ics by binding to microtubules

@en

prefLabel

Maytansine and cellular metabo ...... ics by binding to microtubules

@ast

Maytansine and cellular metabo ...... ics by binding to microtubules

@en

P1433

Q30496972-57D0B61F-CEE6-4B87-B32C-F0A7579B3E26

P1476

Q30496972-69F22972-1B81-4AA9-A807-69EF18150064

P2093

Q30496972-19972027-8FBB-4F22-8679-66F3791963FA

Q30496972-577C9549-F03F-45CA-8FAE-04CA7363A9FD

Q30496972-8C748526-4196-40D4-BA40-F34EDB80ED43

Q30496972-9B1DCAB5-58D9-46B4-A97B-6C071B67A228

Q30496972-A974947E-284E-43A7-9BC3-5EDE10C98511

Q30496972-B9D4FACE-6FB2-4657-8016-A9A5BB97B412

P2860

Q30496972-05016E7B-FE0B-4160-A635-245B0CC55E30

Q30496972-097087B9-B425-4C6C-AFAA-3C2108741895

Q30496972-0C215F11-B6CB-4F93-A76B-B3F7749D4263

Q30496972-26854EB6-CAD8-424F-B7E0-809E619F8031

Q30496972-26E3FFAB-486F-4903-8692-08319ACC5778

Q30496972-28D32FE4-2909-4DB4-99BD-4934B9A4092B

Q30496972-3150947A-F7D1-4A01-99E2-155292B4F2B4

Q30496972-394A7373-3854-4924-B600-8F2B6FC91515

Q30496972-3CD36CB5-3DEF-497D-BD40-A86E5ACA4E1F

Q30496972-49A4ECE9-8581-4CD1-8D12-9B648319AFC8

P304

Q30496972-64484FD9-27EA-4491-AE7B-E981D6CC650B

P31

Q30496972-5F078AB4-4D84-499B-8257-505A5062DCF4

P356

Q30496972-AEDA7D5E-4D09-40D8-BC3D-4AA485C859E4

P433

Q30496972-B15DFDF0-A589-4B50-8682-4FCBE119EADD

P478

Q30496972-CF85A1E4-6C61-4832-8118-D139B1A20693

P50

Q30496972-7220E465-29BE-4FF5-B08B-89E903D93DCF

P577

Q30496972-2EDD6FF3-3EAE-43F2-86A6-E8E8A1D6405D

P5875

Q30496972-9F7221F9-0AFE-496D-9A20-30662EE1BC8F

P698

Q30496972-73E46113-D85B-42C5-96F9-94427645B5C1

P921

Q30496972-20899883-65BC-4805-B410-D41CAF8B9405

Q30496972-E6491B97-CE16-43D6-A894-D7EFCBF5C4BC

P932

Q30496972-1F67D0EE-049A-4824-8E31-EB3F2A658661

P356

1535-7163.MCT-10-0644

P1433

Molecular Cancer Therapeutics

P1476

Maytansine and cellular metabo ...... ics by binding to microtubules

@en

P2093

Emin Oroudjev

http://www.w3.org/2001/XMLSchema#string

Leslie Wilson

http://www.w3.org/2001/XMLSchema#string

Mary Ann Jordan

http://www.w3.org/2001/XMLSchema#string

Ravi Chari

http://www.w3.org/2001/XMLSchema#string

Sharon Wilhelm

http://www.w3.org/2001/XMLSchema#string

Wayne Widdison

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Structural insight into the inhibition of tubulin by vinca domain peptide ligands

Microtubules as a target for anticancer drugs

Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Recent developments in the maytansinoid antitumor agents.

Technology evaluation: cantuzumab mertansine, ImmunoGen.

Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies.

Effects of antimitotic agents on tubulin-nucleotide interactions.

P304

2689-2699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-10-0644

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47395393

http://www.w3.org/2001/XMLSchema#string

P698

20937594

http://www.w3.org/2001/XMLSchema#string

P921

P932

2954514

http://www.w3.org/2001/XMLSchema#string